7EBD6

BRAWN BIOTECH LTD.

August 13, 2026

BSE Limited,
Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400001
Scrip Code: 530207

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on August 13, 2026

Dear Sir/ Ma'am,

Pursuant to the provisions of the Regulation 30 read with Regulation 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**"SEBI Listing Regulations"**), we wish to inform that the Board of Directors of the Company, at its meeting held today, i.e., August 13, 2026, has, *inter-alia*, approved the following:

1. Based on the recommendations of the Audit Committee, the Board has approved the Un-Audited Financial Results for the quarter ended June 30, 2026 along with the limited review report thereon. Financial Results together with Limited Review Report are enclosed as **Annexure - I.**

2. Based on the recommendations of the Audit Committee, the Board has recommended the appointment of M/s G D S M and Co, Chartered Accountants, as Statutory Auditors of the Company, subject to approval of members at forthcoming AGM for a period of 5 years commencing from the conclusion of AGM of the company to be held in the financial year 2026-27 till the conclusion of AGM to be held in 2031. Details as required under the SEBI Listing Regulations are enclosed as **Annexure - II.**

3. Considered and approved Convening of the 41st Annual General Meeting of the Members of the Company through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) on Tuesday, September 29, 2026, along with draft notice convening the meeting to be issued and dispatched to the shareholders for seeking their approval, inter alia, on matters cited in the Notice of AGM.

4. Considered and approved the Boards' Report for the financial year ended March 31, 2026.

The Board meeting commenced at 12:30 P.M. (IST) and concluded at 1.00 P.M. (IST). The aforementioned disclosure is also available on the Company's website: www.brawnbiotech.com. We request you to kindly take the above on record.

Thanking you,
Yours faithfully,
For and on behalf of
Brawn Biotech Limited

BRAWN BIOTECH LIMITED DELHI

Sharma

Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385

Annexure-I

26656

BRAWN BIOTECH LTD.

	BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: C-64 Lajpat Nagar-1 Delhi 110024				
	STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026				Rs. In Lacs
Sr.	Particulars	Quarter Ended			Year Ended
No.		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		Un-audited	Audited	Un-audited	Audited
1	**Revenue from operations**				
	Revenue from operations	607.88	197.65	579.77	1,697.77
	Other Income	13.85	18.09	9.09	45.40
	Total Revenue	**621.74**	**215.74**	**588.86**	**1,743.18**
2	**Expenses**				
a	Cost of material consumed	-	-	-	-
b	Purchase of stock-in-trade	223.50	130.12	391.21	1,411.44
c	Change in inventories of finished goods, work in progress and stock in trade	295.34	41.32	104.92	40.49
d	Employee Benefit expenses	30.55	19.21	20.52	68.36
e	Depreciation and amortisation expenses	2.99	3.00	3.07	12.20
f	Finance Cost	0.02	0.23	0.03	0.45
g	Other expenses	53.90	57.48	45.51	210.13
	Total Expenses	**606.30**	**251.36**	**565.26**	**1,743.07**
3	**Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)**	15.44	(35.62)	23.60	0:11
4	**Other Income**	-	-	-	-
5	**Profit from ordinary activities before exceptional items (3-4)**	15.44	(35.62)	23.60	0.11
6	**Exceptional Items**	-	-	-	-
7	**Profit from ordinary activities before tax (5-6)**	15.44	(35.62)	23.60	0.11
8	**Tax Expenses**		(93.95)		(93.95)
9	**Profit (Loss) for the period from continuing operations (7-8)**	15.44	58.34	23.60	94.06
10	**Profit/(loss) from discontinuing operations**	-	-	-	-
11	**Tax expense of discontinuing operations**	-	-	-	-
12	**Profit/(loss) from Discontinuing operations (after tax) (10-11)**	-	-	-	-
13	**Profit (Loss) for the period (9+12)**	15.44	58.34	23.60	94.06
14	**Other Comprehensive Income**	0.09	0.08	3.20	3.65
	Total Comprensive Income	15.53	58.41	26.80	97.71
15	Details of equity share capital	300.03	300.03	300.03	300.03
	Paid-up equity share capital				
	Face value of equity share capital				
16	Reserve excluding Revaluation Reserve				
17	Earnings per share				
i	Basic earnings per share	0.52	1.95	0.89	3.26
ii	Diluted earnings per share	0.52	1.95	0.89	3.26

NOTES :-

1. Results for the quarter ended on 30th June, 2026 were reviewed by the Audit committee and then approve by the Board of Directors at their meeting held on 13th August, 2026.
2. The Statutory Auditors carried out the limited review for quarter ended 30th June, 2026. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
3. The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
4. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
5. The above Standalone Un- audited Financial Results for the quarter ended on 30.06-2026 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
6. Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Date : 13-08-2026
Place: Delhi

BRAWN BIOTECH LIMITED
DELHI

RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited**for the quarter ended 30th June 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility and approved bythe Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai& Associates
Chartered Accountants
Firm Registration No. 018764N

Rajeev Jain

Rajiv Udai & Associates
INDIA
FRN:018764N
DELHI
Chartered Accountants

Rajeev Jain
Partner
Membership No. 099767
UDIN: 26099767HZLTHW2096

Place:Delhi
Date:13-08-2026

Head Office : A-36, 1st Floor, Guru Nanak Pura, Near Metro Pillar No. 57, Vikas Marg, Laxmi Nagar, Delhi-110092
Branches : Gurugram (Haryana), Indore (Madhya Pradesh), Noida (Uttar Pradesh)
Phone : 011-49027875 | **Mobile** : 93122 53876, 8700727072 | **E-mail** : info@rajivudai.com, rajiv@rajivudai.com
Web. : www.rajivudai.com

Annexure - II

Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read SEBI Master Circular dated January 30, 2026

S.No	Details of events	Particulars
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~	Appointment of M/s G D S M and Co (FRN: 034194N), Chartered Accountants as Statutory Auditors of the Company.
2.	Date of appointment/ ~~reappointment/ cessation (as applicable)~~ & term of appointment/ ~~reappointment~~	Based on the recommendations of the Audit Committee, the Board of Directors at its Meeting held today recommended the appointment of M/s. G D S M and Co (FRN: 034194N), Chartered Accountants, as the Statutory Auditors of the Company for a term of five years i.e. from the conclusion of the 41st Annual General Meeting until the conclusion of the 45th Annual General Meeting, subject to approval of the Shareholders.
3.	Brief profile (in case of appointment)	M/s G D S M and Co is a Chartered Accountant firm offering full range of services, including Audit under Companies Act, Income Tax, GST Audit, Internal Audit, Consultancy in Taxation related matters including Income Tax, GST, Sales tax, Service Tax, Company Law matters, Labour Laws, etc.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

BRAWN BIOTECH LIMITED
DELHI

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF BRAWN BIOTECH LIMITED ('THE COMPANY') HELD ON THURSDAY, 13TH DAY OF AUGUST 2026 AT ITS REGISTERED OFFICE SITUATED AT C-64 LAJPAT NAGAR - 1, FIRST FLOOR, DELHI 110024, WHICH COMMENCED AT 12.30 PM AND CONCLUDED AT 1.00 PM

APPROVAL OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE, 2026

The Chairman informed the Board that, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026 were required to be considered and approved by the Board within forty-five days from the end of the quarter. The Chairman further informed that the Audit Committee, at its meeting held on August 13, 2026, had reviewed and recommended the said financial results to the Board for approval, along with the Limited Review Report issued by the Statutory Auditors of the Company thereon.

After Discussion & deliberation, the following resolution has been passed by the Board unanimously:

"**RESOLVED THAT** pursuant to Regulation 33 and other applicable regulations, if any, of the SEBI LODR Regulations, and based on the recommendation of the Audit Committee at its meeting held on August 13, 2026, the Unaudited Financial Results of the Company for the quarter ended 30th June 2026, together with the Limited Review Report dated August 13, 2026 issued thereon by Statutory Auditors of the Company, as placed before the meeting, be and are hereby considered and approved.

RESOLVED FURTHER THAT Mr. Brij Raj Gupta, Director of the Company be and is hereby authorized to sign the Un-audited financial results for the quarter ended 30th June 2026 and submit the same with stock exchange and other concerned authority."

For and on behalf of
Brawn Biotech Limited

BRAWN BIOTECH LIMITED DELHI

Sharma

Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385

CFO CERTIFICATE UNDER REGULATION 33(2)(a) OF SEBI (LODR) REGULATION, 2015

To
The Board of Directors
Brawn Biotech Limited
First Floor, C-64 Lajpat Nagar-1,
Delhi, 110024.

A. I have reviewed Un-Audited Financial Results of Brawn Biotech Limited for the quarter ended 30th June 2026 and to the best of my knowledge and belief that;

a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.

b) These statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

B. There are, to the best of my knowledge and belief, no transaction entered into by the listed entity during the quarter ended 30th June 2026 which are fraudulent, illegal or violative of the listed entity's code of conduct.

C. I have indicated to the Auditors and the Audit Committee that there are no significant changes in internal control over financial reporting during the quarter and no instances of significant fraud with which they have become aware.

For Brawn Biotech Limited

Rati Garg
Chief Financial Officer

Date: 13.08.2026
Place: Delhi